logo
Share SHARE
FONT-SIZE Plus   Neg

Bayer Updates US Labels For Drospirenone-containing Combined Oral Contraceptives

Bayer HealthCare, a subgroup of Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK), said the company and U.S. Food and Drug Administration, or FDA, have agreed to update the labels for its drospirenone-containing combined oral contraceptives, or COCs, in United States.

The updated labels in the U.S. include additional information from recently published studies evaluating the risk of venous thromboembolism (blood clots) in women taking drospirenone-containing COCs. Mainly, the new U.S. labels state that COCs containing drospirenone may be associated with a higher risk of venous thromboembolism, or VTE, than COCs containing levonorgestrel or some other progestins, Bayer HealthCare noted.

Epidemiologic studies that compared the risk of VTE reported that the risk ranged from no increase to a three-fold increase. The U.S. labels state that before initiating use of drospirenone-containing COCs in a new COC user or a woman who is switching from a contraceptive that does not contain drospirenone, consider the risks and benefits of a drospirenone containing COC in light of her risk of a VTE.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The holiday throng seeking to take a flight out to their preferred destinations at the at New York's Kennedy International Airport ahead of the Memorial Day holiday were in for a rude shock. Technology played a spoilsport, as a computer system broke down Sunday evening at a terminal, causing flight delays and cancellations that resulted in manual check-in process for thousands of holiday passeng The month of May saw the FDA greenlight 5 new drugs, including 1 new molecular entity, and surprisingly turn down 1 drug candidate, whose approval was considered a no-brainer by some experts. Lab equipment maker Thermo Fisher Scientific Inc. has agreed to acquire electron microscope maker FEI Co. for about $4.2 billion in cash, the two companies said Friday. Thermo Fisher noted that FEI's electron microscopy platform will complement its own mass spectrometry systems to accelerate advancements in structural biology.
comments powered by Disqus
Follow RTT